AZA+Lus VS AZA Monotherapy in HR-MDS

NCT06927232 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

86

Enrollment

OTHER

Sponsor class

Conditions

Higher-risk Myelodysplastic Syndrome

Interventions

DRUG: Azacitidine (AZA)
DRUG: Luspatercept

Sponsor

Peking Union Medical College Hospital